• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Bausch + Lomb (BLCO) Stock Could Be Reasonable Despite A 35% Rise

    Simply Wall St·11/14/2026 03:27:51
    Listen to the news

    Bausch + Lomb shares have climbed to around US$21.09, and the recent momentum puts fresh focus on whether the current market value can be explained by the cash the business is expected to generate. With the stock now on many investors' watchlists, the central issue is how that price stacks up against its projected cash flows using a Discounted Cash Flow (DCF) lens.

    • The share price has returned 35.2% over the past year, which raises the question of whether that gain is supported by the cash the business can realistically produce over time.
    • The company relies on ongoing demand for eye health products and execution on its cost base, which can directly influence how efficiently current earnings turn into future cash flows available to shareholders.
    • Prefer to judge Bausch + Lomb on sales? See what Bausch + Lomb's 1.4x P/S says about the price.

    For investors, the debate is whether Bausch + Lomb's recent share price strength is adequately backed by its cash flows when weighed against an intrinsic value estimate built from those cash streams.

    If you are weighing whether Bausch + Lomb's 35.2% one year return matches its cash flow profile, it can help to compare that question with a focused list of 32 high quality undervalued stocks.

    Does Bausch + Lomb Look Undervalued on Cash Flow?

    The Discounted Cash Flow (DCF) approach looks at what Bausch + Lomb could return to shareholders in future and brings those cash streams back to today. On this model, the latest twelve month free cash flow sits at about $212.6 million, which is the base for the forecast. Analysts and internal estimates then step that figure up to higher annual free cash flows later in the decade, implying a growing rather than shrinking cash engine.

    Those cash forecasts, once discounted back, add up to an estimated intrinsic value that the DCF output places substantially above the current share price of $21.09. For anyone tracking Bausch + Lomb after its recent share price move, the model is effectively saying the market is assigning a lower value to those projected cash flows than the DCF would justify. Find out what Bausch + Lomb could be worth using our Discounted Cash Flow (DCF) estimate.

    The Bausch + Lomb Narrative: What Would Justify Today's Price?

    Narratives for Bausch + Lomb pick up where the DCF puzzle leaves off, spelling out which paths for revenue growth, profitability and earnings would need to play out for the equity to trade materially higher or lower than it does today on Simply Wall St's Community page. Rather than relying on a single output, each scenario lays out its own fair value assumptions so you can compare those expectations with the company’s actual results as they are reported.

    Views on Bausch + Lomb are now split between those who see more upside in the story and those who think expectations already run hot.

    Bull case: roughly fairly valued

    The analyst consensus Narrative on Simply Wall St focuses on product demand and margin improvements to support the upside case.

    "Disciplined execution under the Vision 27 financial excellence program, including SG&A mix optimization, manufacturing efficiencies and focused R&D spend on near to mid term launch assets, is expected to support adjusted EBITDA growth above sales growth and drive expanding net margins and earnings power…"

    Discover why this Narrative puts Bausch + Lomb at roughly fairly valued.

    Bear case: 17% overvalued

    The bearish analyst Narrative on Simply Wall St focuses more heavily on capital efficiency concerns.

    "Although contact lenses and consumer eye care products are adding volume globally, the history of weaker earnings per share and free cash flow margins, together with low ROIC, implies that even steady Vision Care growth may continue to require significant marketing and manufacturing spend, leaving limited room for net margin expansion…"

    Explore why this Narrative puts Bausch + Lomb at 17% overvalued.

    Bausch + Lomb’s value story still hinges on who is steering it

    The cash flow debate only goes so far without knowing who is making the key calls at Bausch + Lomb, how their incentives are structured, and whether those rewards align with long term shareholders. See who runs Bausch + Lomb and how they are paid.